コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 a) (CIA) remains a major unsolved problem in clinical oncology.
2 Concerns for patient safety persist in clinical oncology.
3 Cancer Research and the American Society of Clinical Oncology.
4 both Clinical Cancer Research and Journal of Clinical Oncology.
5 multidrug resistance is a central problem in clinical oncology.
6 of 1,000 members of the American Society for Clinical Oncology.
7 IgE-based anticancer immunotherapy in human clinical oncology.
8 e information has become routine practice in clinical oncology.
9 ntibodies is an indispensable cornerstone of clinical oncology.
10 spectives of CTCs and ctDNA as biomarkers in clinical oncology.
11 vely few agents have found widespread use in clinical oncology.
12 r biology, and the widespread use of MTDs in clinical oncology.
13 ent cyto-immunotherapeutic with potential in clinical oncology.
14 ians, academics, and the American Society of Clinical Oncology.
15 relationship, tumor biology, immunology, and clinical oncology.
16 el P. Link, MD President American Society of Clinical Oncology.
17 rapy and offer a perspective on the state of clinical oncology.
18 09 Annual Meeting of the American Society of Clinical Oncology.
19 ed this article for submission to Journal of Clinical Oncology.
20 onal cancer research, given its relevance in clinical oncology.
21 tial paradigm for differentiation therapy in clinical oncology.
22 Schilsky, MD President American Society of Clinical Oncology.
23 mple of differentiation-induction therapy in clinical oncology.
24 provement program of the American Society of Clinical Oncology.
25 is needed to ensure high-quality research in clinical oncology.
26 ents one of the major unresolved problems of clinical oncology.
27 erapy-induced alopecia is a major problem in clinical oncology.
28 in new therapeutics that have revolutionized clinical oncology.
29 t few decades and now play a central role in clinical oncology.
30 olytic viruses could enter the mainstream of clinical oncology.
31 the 2004 meeting of the American Society of Clinical Oncology.
32 lular pharmacology of anthracyclines and for clinical oncology.
33 bership directory of the American Society of Clinical Oncology.
34 esis, and its current and projected roles in clinical oncology.
35 99 Annual Meeting of the American Society of Clinical Oncology.
36 mpact that expression profiling will have on clinical oncology.
37 finally, the management of allergy in daily clinical oncology.
38 he design of immunotherapeutics relevant for clinical oncology.
39 ive multicenter comparative trials in modern clinical oncology.
40 an Cancer Society or the American Society of Clinical Oncology.
41 Cancer Journal for Clinicians and Journal of Clinical Oncology.
42 for Cancer Research and American Society of Clinical Oncology.
43 f Controlled Trials, and American Society of Clinical Oncology abstracts were searched for cohort stu
44 cent guidelines from the American Society of Clinical Oncology advocate the inclusion of HIV-infected
46 ritten permission by the American Society of Clinical Oncology, American Society for Radiation Oncolo
48 d and abstracts from the American Society of Clinical Oncology, American Society of Hematology, and t
52 n Cancer Society and the American Society of Clinical Oncology and has been published jointly by invi
54 is an initiative of the American Society of Clinical Oncology and its Institute for Quality that add
57 cular biology, health services research, and clinical oncology and the advocacy community, with a com
58 ations and efficacy, the American Society of Clinical Oncology and the American Society of Hematology
59 by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Labora
60 ollaboration between the American Society of Clinical Oncology and the College of American Pathologis
63 eting proceedings of the American Society of Clinical Oncology and the European Society of Medical On
64 for them periodically in both the Journal of Clinical Oncology and the Journal of Oncology Practice.
65 stracts presented at the American Society of Clinical Oncology and the San Antonio Breast Cancer Symp
66 practice guidelines, point-of-care needs in clinical oncology, and federal policy issues and implica
67 ege of Chest Physicians, American Society of Clinical Oncology, and National Comprehensive Cancer Net
68 ion for Cancer Research, American Society of Clinical Oncology, and the American Association for Canc
69 ociety for Neuroscience, American Society of Clinical Oncology, and the Radiological Society of North
70 The abstracts of the American Society of Clinical Oncology Annual Meeting between 1995 and 2014 a
71 stracts presented at the American Society of Clinical Oncology annual meetings (2004 to 2010), the Wo
72 stracts presented at the American Society of Clinical Oncology annual meetings from 2004 to 2007 were
74 conducted as part of the American Society of Clinical Oncology (ASCO) 2001 Presidential Initiative to
75 se The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for
76 o cancer prevention, the American Society of Clinical Oncology (ASCO) advocates a fundamental reform
78 s the development of the American Society of Clinical Oncology (ASCO) and explores the role of its me
79 is an initiative of the American Society of Clinical Oncology (ASCO) and its Institute for Quality,
81 recommendations from the American Society of Clinical Oncology (ASCO) and the European Organisation f
84 stracts presented at the American Society of Clinical Oncology (ASCO) and the European Society of Med
85 Representatives from the American Society of Clinical Oncology (ASCO) and the National Comprehensive
87 e Annual Meetings of the American Society of Clinical Oncology (ASCO) and the San Antonio Breast Canc
88 For that reason, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Onc
91 vention Committee of the American Society of Clinical Oncology (ASCO) believes that a proactive stanc
92 PURPOSE In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approv
93 In December 2016, the American Society of Clinical Oncology (ASCO) Board of Directors approved the
96 result identified by the American Society of Clinical Oncology (ASCO) Cancer Research Committee to th
100 athology (ASCP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to con
101 Pathology (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to dev
108 e recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genet
111 y recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-m
120 ts founding in 1964, the American Society of Clinical Oncology (ASCO) has been committed to improving
125 experts, members of the American Society of Clinical Oncology (ASCO) Health Services Committee, and
126 n outside reviewers, the American Society of Clinical Oncology (ASCO) Health Services Research Commit
130 For the third year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer A
131 nd consecutive year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer A
132 for the first time, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer A
134 of its relevance to the American Society of Clinical Oncology (ASCO) membership, ASCO endorsed the g
135 nce of this guideline to American Society of Clinical Oncology (ASCO) membership, ASCO reviewed the g
143 lists to update the 2012 American Society of Clinical Oncology (ASCO) provisional clinical opinion (P
146 Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS ha
148 risk parameters from the American Society of Clinical Oncology (ASCO) recommendation did not add powe
149 0% of the members of the American Society of Clinical Oncology (ASCO) reside and practice outside US
151 program developed by the American Society of Clinical Oncology (ASCO) to aid oncology practices in qu
152 irs (SPGA) Committee and American Society of Clinical Oncology (ASCO) Tobacco Cessation and Control S
153 ent Program (LDP) of the American Society of Clinical Oncology (ASCO), a group of participants was ch
154 he 2006 guideline of the American Society of Clinical Oncology (ASCO), a systematic review of the lit
158 Purpose To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (S
160 ng patient HER2 results, American Society of Clinical Oncology (ASCO)/College of American Pathologist
161 biologic agents published in the Journal of Clinical Oncology between January 1, 2006 and June 30, 2
162 American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guidel
163 ly predicted to become a standard of care in clinical oncology, but more effective data sharing to ac
166 er Cancer Foundation and American Society of Clinical Oncology (Career Development Award); The Trust
167 Cancer Foundation of the American Society of Clinical Oncology, Cleveland Clinic Research Programs Co
168 rable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published
169 r new standards (eg, the American Society of Clinical Oncology/College of American Pathologists [ASCO
170 The study supports the American Society of Clinical Oncology/College of American Pathologists and C
171 2013 updates to the 2007 American Society of Clinical Oncology/College of American Pathologists recom
172 the 2013 updates to the American Society of Clinical Oncology/College of American Pathologists recom
177 2012 and March 2013, the American Society of Clinical Oncology conducted a survey of US oncologists e
178 d abstracts presented at American Society of Clinical Oncology conferences held between January 2000
179 , abstracts presented at American Society of Clinical Oncology conferences held between January, 2000
181 dence-Based Care and the American Society of Clinical Oncology convened a Joint Expert Panel in Augus
184 cologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted
192 ms, assessing their institution's methods of clinical oncology education and their perspective on opt
194 ement of policy from the American Society of Clinical Oncology encourages the Secretary of the United
196 culty rated the value of nearly all types of clinical oncology exposure significantly lower than did
199 e annual meetings of the American Society of Clinical Oncology (from 1999 to 2010), at the first Inte
200 a focused update of the American Society of Clinical Oncology guideline concerning use of postmastec
201 RPOSE To update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventio
203 agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in
207 r over three decades, a mainstay and goal of clinical oncology has been the development of therapies
208 latelet transfusion, the American Society of Clinical Oncology has developed practice guidelines desi
210 lity of TERT-based adoptive immunotherapy in clinical oncology, highlighting, for the first time, the
214 clinical application of IgE-derived drugs in clinical oncology is clear if the antitumor activity of
217 one of the fundamental unsolved problems of clinical oncology - is driven in part by defined abnorma
219 nd related phase III trials published in six clinical oncology journals in the last 3.5 years were an
221 became available to all American Society of Clinical Oncology member physicians in 2006 as a volunta
224 Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendatio
225 that are either already approved for use in clinical oncology or currently under preclinical or clin
226 s and presenters who published in Journal of Clinical Oncology or who presented an abstract at the AS
227 revised opinion based on American Society of Clinical Oncology panel consensus in the context of an e
234 dies, including the 2004 American Society of Clinical Oncology presentation, described in this paper
236 r Institute's (NCI) Minority-Based Community Clinical Oncology Program (MBCCOP) seeks to enhance mino
242 ces participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative i
243 nsive Cancer Network and American Society of Clinical Oncology recommend consideration of the use of
244 an Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoie
245 ve revisions to the 2006 American Society of Clinical Oncology recommendations were warranted, but cl
247 Against Cancer From the American Society of Clinical Oncology" represent the invaluable contribution
248 e assessment of cardiorespiratory fitness in clinical oncology research has increased substantially o
255 manuscript presents the American Society of Clinical Oncology's (ASCO's) ethical framework for incor
256 This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptatio
258 is article addresses the American Society of Clinical Oncology's (ASCO's) vision for improved communi
260 de (SLN) biopsy based on American Society of Clinical Oncology/Society of Surgical Oncology recommend
261 a tool to assess trainees' knowledge of the clinical oncology subspecialty, establish consistency in
262 mission tomography has broad implications in clinical oncology, such as diagnosis, staging, and monit
263 2004 proceedings of the American Society of Clinical Oncology, the 2003 and 2004 proceedings of the
264 ted therapeutics become increasingly used in clinical oncology, the ability to quantify protein expre
265 nt was obtained from the American Society of Clinical Oncology, the American Society of Hematology, a
266 anizations including the American Society of Clinical Oncology, the European Organization for Researc
267 ed randomized trials published in Journal of Clinical Oncology, the New England Journal of Medicine,
269 ry, and engineering with cancer research and clinical oncology through education, outreach, and colla
271 applied recently in an article in Journal of Clinical Oncology to measure the impact of using a genom
272 of high-voltage electrical pulses (HVEPs) in clinical oncology to treat solid tumors with irreversibl
273 ies, including those published in Journal of Clinical Oncology , to patients seen in their own clinic
274 R pathway, cell death and the immune system, clinical oncology) to discuss the latest developments in
275 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
276 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
277 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
278 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
279 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
280 dies, including those published inJournal of Clinical Oncology, to patients seen in their own clinica
281 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
282 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
283 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
284 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
285 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
286 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica
288 ing children in appropriately designed adult clinical oncology trials is feasible and can be done in
289 is being pursued as a therapeutic target in clinical oncology trials, its effects on metastasis, the
290 tcomes (PROs) have become a key component of clinical oncology trials, many challenges exist regardin
293 nical Benefit Scale, the American Society of Clinical Oncology Value Framework, and the National Comp
294 Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all ho
295 alyses performed for the American Society of Clinical Oncology VTE Guidelines Committee and the Cochr
296 y a Working Group of the American Society of Clinical Oncology were reviewed with attention to prespe
297 the guidelines from the American Society of Clinical Oncology, which suggest that all patients of ch
298 rporating AI and machine learning tools into clinical oncology, with an emphasis on biomarker develop
299 y populations; increase the diversity of the clinical oncology workforce as a requisite to improving
300 Research Service Award, American Society of Clinical Oncology Young Investigator Award, MSK's Ludwig